American Regent v. Long Grove Pharmaceuticals: Selenious Acid Patent Consolidated
American Regent, Inc. asserted US11998565B2 — covering injectable selenious acid formulations — against Long Grove Pharmaceuticals in New Jersey federal court. Filed in July 2024, the action was one of 13 parallel ANDA infringement suits against generic challengers, consolidated into a single lead action within 128 days.
13-Defendant ANDA Wave Targets Generic Selenium Injection Market
On July 16, 2024, American Regent, Inc. (ARI) filed Civil Action No. 2:24-cv-07804 in the District of New Jersey against Long Grove Pharmaceuticals, LLC, asserting infringement of US11998565B2. The patent covers selenious acid injectable formulations used as an intravenous selenium supplement — a critical trace element product administered to patients on parenteral nutrition. ARI simultaneously filed 12 substantially identical actions against other generic pharmaceutical companies on the same day.
The action was terminated on November 21, 2024, not on the merits, but through court-ordered consolidation. All 13 related actions — including suits against Accord Healthcare, Cipla, Dr. Reddy’s, Hikma, Sun Pharmaceutical, and Zydus, among others — were merged into lead case 2:24-cv-7791 by stipulation of all parties. Going forward, Long Grove and all co-defendants participate in unified proceedings under a consolidated caption, which is standard practice for coordinated ANDA litigation in the District of New Jersey.
The 128-day period from filing to consolidation is consistent with efficient case management in multi-defendant Hatch-Waxman litigation, where parallel ANDA filings against a common innovator product frequently trigger consolidation motions early in proceedings. The substantive questions — patent validity, claim scope, and non-infringement defenses — remain entirely unresolved in the public record. What drove consolidation was judicial efficiency, not any concession by either party on the merits.
Filing to Case Consolidated in 128 days
128 days to consolidation — typical for coordinated ANDA wave litigation in NJ District Court
Case consolidated: what the transfer to lead docket means for both parties
Consolidation is procedural — not a merits ruling
When a district court consolidates related actions under Fed. R. Civ. P. 42(a), it merges separately docketed cases into a single proceeding for efficiency. No claim is dismissed, no patent is adjudicated valid or invalid, and no infringement finding is made. Long Grove’s individual docket (2:24-cv-07804) is closed as a standalone case, but the dispute continues under the lead case caption. All defenses remain fully available.
Procedural — no merits adjudicationARI gains coordinated enforcement across all 13 ANDA filers
Consolidation typically benefits the patent holder in multi-defendant ANDA litigation: a single discovery schedule, unified claim construction, and one Markman hearing apply to all defendants simultaneously. American Regent avoids duplicative proceedings and inconsistent rulings across parallel dockets. The 30-month stay triggered by timely Hatch-Waxman filing remains in effect for each ANDA applicant pending consolidated resolution.
Unified enforcement — 30-month stay intactLong Grove joins consolidated defense alongside 12 co-defendants
Long Grove Pharmaceuticals now litigates within a consolidated proceeding alongside Accord, Cipla, Dr. Reddy’s, Hikma, Sun Pharma, Zydus, and others. This may create opportunities for shared invalidity arguments and cost-sharing on prior art searches, but also reduces each defendant’s individual procedural control. Settlement dynamics in multi-defendant ANDA consolidations often reflect the relative commercial stakes of each ANDA applicant’s product launch timeline.
Co-defendant consolidation — shared proceedingsGeneric selenium injection market entry now turns on one consolidated outcome
With 13 ANDA applicants consolidated before a single judge, the outcome of the US11998565B2 litigation will effectively determine market access for the entire first wave of generic selenious acid injectable products. A finding of invalidity or non-infringement would open the market to multiple generic entrants simultaneously. Conversely, an injunction sustaining ARI’s patent would protect the branded selenium injection franchise across all three dosage strengths through patent expiry.
Multi-generic market entry at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical manufacturer and innovator — holder of US11998565B2 for selenious acid injectionSearch in Eureka ↗ |
| Defendant | LONG GROVE PHARMACEUTICALS, LLC | Company | Generic pharmaceutical company; ANDA applicant challenging ARI’s selenious acid patentSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeffrey A. Cohen | Attorney | Counsel for LONG GROVE PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant law firm | Flaster Greenberg PC | Law Firm | Representing LONG GROVE PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated consolidation order reflects coordinated case management rather than any adjudication of the underlying patent dispute. The verdict text documents that all 13 actions share a common plaintiff (ARI), a common asserted patent, and a common reference listed drug — the threshold for consolidation under Rule 42(a). The order is silent on infringement, validity, and claim scope, meaning no legal or factual precedent is established by this termination. Both parties retain their full litigation positions in lead case 2:24-cv-7791.
US11998565B2 — Selenious Acid Injectable Selenium Formulations
US11998565B2, filed under application number US18/124391, protects selenious acid injectable formulations used to deliver selenium intravenously to patients who cannot absorb nutrients orally — particularly those on total parenteral nutrition (TPN). The patent covers three commercially distinct concentration formats: 600 mcg selenium per 10 mL vial, 60 mcg selenium per mL, and 12 mcg selenium per 2 mL. Selenium is an essential trace element; its deficiency in TPN patients carries serious clinical risk, making this a medically necessary product category with a defined hospital and compounding market.
The commercial significance of US11998565B2 lies in its ability to block generic market entry across all three dosage presentations simultaneously. ARI’s decision to assert this patent against 13 ANDA applicants in a single enforcement wave signals confidence in claim breadth and a strategy to preserve exclusivity through the Hatch-Waxman 30-month stay. For competitors and FTO analysts, the patent’s formulation claims — covering specific concentration ranges and selenium speciation — are the critical scope questions that will be resolved in the consolidated New Jersey proceedings.
Should you run an FTO against US11998565B2?
Any company developing, manufacturing, or commercialising injectable selenious acid products — particularly those targeting the parenteral nutrition market — should treat US11998565B2 as a live freedom-to-operate risk. With 13 ANDA applicants already in consolidated litigation, the patent’s enforceability is actively contested but not yet adjudicated. Product teams working on selenium injection formulations at any of the three concentration levels claimed should assess whether their formulation parameters fall within or outside the asserted claim scope before committing to commercialisation timelines.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map the specific concentration and formulation claims of US11998565B2 against your product specifications in minutes. Eureka can identify related family members, continuation risk, and prosecution history disclaimers that may affect claim interpretation — critical intelligence ahead of any Markman ruling in the 2:24-cv-7791 consolidated action. Set up a patent monitoring alert to track claim construction orders and any inter partes review filings against this patent as the litigation progresses.
Run a freedom-to-operate analysis on US11998565B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Litigation: Injectable Pharmaceutical Formulation Cases in NJ
Explore parallel Hatch-Waxman consolidation cases involving injectable pharmaceutical formulation patents litigated in the District of New Jersey.
What this case signals for the parenteral nutrition IP landscape
A 13-defendant consolidation on a single selenium injection patent is a high-stakes template for ANDA wave enforcement strategy in injectable pharmaceutical markets.
Coordinated ANDA filing waves trigger rapid consolidation in NJ District Court
American Regent’s simultaneous filing against 13 generic defendants on the same day illustrates a deliberate enforcement architecture. When multiple ANDAs reference the same reference listed drug, patent holders can file in parallel and seek consolidation immediately — compressing the timeline to a single dispositive ruling and maximising the 30-month stay period.
US11998565B2 covers multiple dose strengths — claim scope is commercially critical
The asserted patent covers three distinct selenious acid formulations (600 mcg/10 mL, 60 mcg/mL, and 12 mcg/2 mL). Generic defendants whose ANDAs target only one dosage strength may have narrower infringement exposure, but claim construction in the consolidated proceeding will bind all parties. Early monitoring of the Markman briefing schedule in lead case 2:24-cv-7791 is advisable.
American v LONG — key questions answered
The case was closed on November 21, 2024, via consolidation into lead case 2:24-cv-7791, not through any merits ruling. Long Grove Pharmaceuticals continues to litigate alongside 12 other generic defendants in the consolidated New Jersey District Court action. No finding on infringement or patent validity has been made.
American Regent asserts US11998565B2, filed under application US18/124391, which covers selenious acid injectable formulations providing selenium at concentrations of 600 mcg/10 mL, 60 mcg/mL, and 12 mcg/2 mL. These formulations are used as selenium supplementation in patients receiving total parenteral nutrition.
American Regent filed 13 substantially identical infringement actions on the same day against different generic ANDA applicants referencing the same reference listed drug and the same patent. All parties stipulated to consolidation under Rule 42(a) to avoid duplicative discovery, inconsistent claim construction rulings, and judicial inefficiency. Consolidation is standard practice in coordinated Hatch-Waxman enforcement waves in the District of New Jersey.
The consolidated lead case 2:24-cv-7791 includes Accord Healthcare, Aspiro Pharma, Cipla USA and Cipla Limited, Dr. Reddy’s Laboratories, Eugia Pharma Specialities and Eugia US, Gland Pharma, Hikma Pharmaceuticals USA, Long Grove Pharmaceuticals, RK Pharma, Somerset Therapeutics and affiliates, Sun Pharmaceutical Industries, Xiromed, and Zydus Pharmaceuticals — 13 actions in total.
Consolidation is a procedural case management tool and does not itself alter the 30-month stay clock triggered by timely Hatch-Waxman notice letters. Each defendant’s stay period is calculated from the date ARI received the relevant Paragraph IV certification notice. The consolidated proceedings must resolve patent validity and infringement before any defendant can lawfully launch a generic selenious acid product absent a court finding of invalidity or non-infringement.
PatSnap Eureka searches patents and litigation data to answer instantly.